Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.405
-0.055 (-2.24%)
Apr 22, 2026, 1:02 PM EDT - Market open
Alector Revenue
In the year 2025, Alector had annual revenue of $21.05M, down -79.07%. Alector had revenue of $6.24M in the quarter ending December 31, 2025, a decrease of -88.50%.
Revenue (ttm)
$21.05M
Revenue Growth
-79.07%
P/S Ratio
12.90
Revenue / Employee
$204,320
Employees
103
Market Cap
265.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | -79.51M | -79.07% |
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Coherus Oncology | 42.17M |
| C4 Therapeutics | 35.95M |
| Foghorn Therapeutics | 30.91M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 4.51M |
| Inhibikase Therapeutics | 1.00 |
ALEC News
- 7 weeks ago - Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Alector to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - GlobeNewsWire
- 5 months ago - Alector to Participate in the Bank of America CNS Therapeutics Conference - GlobeNewsWire
- 5 months ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 months ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 6 months ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire